Sign up to EURETINA

10.45
B. Chanana INDIA
Management of dropped IOL and nucleus

10.51
S.J. Chen TAIWAN
Inadvertent globe perforation during local anaesthesia for cataract surgery and its Management

10.57
H. Heimann UK
Retinal detachment in mismanaged cataract surgery: Prevention, etiology, and management

11.03
K. Fong MALAYSIA
Cystoid macular edema: When and how to treat?

11.09
M. Zinckernagel SWITZERLAND
Endophthalmitis: early detection, differentiation from sterile reaction, and management

11.15
Discussion

11.30
End of session

Fri 02 11:00 - 11:45 CEST

EURETINA Session 1: The EURETINA Guidelines for the Management of Retinal Disease: The Next Steps

Chairperson(s):
U. Schmidt-Erfurth AUSTRIA, A. Loewenstein ISRAEL

Channel 1

11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds

11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance

11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery

11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever

11.24
C.C.W. Klaver THE NETHERLANDS
The myopia pandemic: The European response

11.30
Discussion

11.45
End of session

Fri 02 11:45 - 12:30 CEST

Instructional Course 2: How to Deal with an Intraocular Foreign Body

Chairperson(s):
G. Pertile ITALY, G. Prigione ITALY

Channel 3

11.45
G. Pertile ITALY
Introduction

11.47
G. Prigione ITALY
Strategies to deal with an intraocular foreign body

11.54
G. Caputo FRANCE
Foreign bodies and perforating traumas in children

12.01
H. Mortada
Management of late complications correlated with foreign body injuries

12.08
G. Pertile ITALY
Pitfalls in removing intraocular foreign bodies

12.15
Discussion

12.30
End of session

Fri 02 11:45 - 12:30 CEST

Symposium Session 2: UNICORN – Standardization and definition of qualitative and quantitative OCT-A parameters

Chairperson(s):
M. Munk SWITZERLAND, N. Waheed USA, S. Vujosevic ITALY

Channel 2

11.45
S. Vujosevic ITALY
Nomenclature of qualitative and quantitative OCTA parameters

11.53
M. Munk SWITZERLAND
Consensus on OCTA metrics in retinal vascular diseases and standardization of OCTA parameters in clinical trials

12.01
F. Pichi UAE
Consensus on OCTA metrics in inflammatory diseases

12.09
U. Chakravarthy UK
The Unicorn: Expert consensus on OCT A nomenclature in exudative AMD

12.17
Discussion

12.30
End of session

Fri 02 12:00 - 12:45 CEST

EURETINA Session 2: Management of COMPLEX RRD

Chairperson(s):
A. Laidlaw UK, J. Garcia-Arumi SPAIN

Channel 1

12.00
A. Laidlaw UK
Realistic expectations in complex retinal detachment surgery

12.05
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?

12.10
J. Garcia-Arumi SPAIN
PVR, when how and what to peel

12.15
T. Williamson UK
Retinectomy in PVR: early vs late

12.20
J.C. Pastor SPAIN
Risks with Tamponade agents

12.25
Discussion

12.45
End of session

Fri 02 13:45 - 14:30 CEST

Instructional Course 3: New Frontiers in Diagnosis & Treatment of Diffuse Diabetic Macular Edema

Chairperson(s):
D. E. Pelayes ARGENTINA

Channel 3

13.45
M. Batataglia Parodi ITALY
Multimodal diagnostic tools in DME

13.50
R. Cano Hidalgo MEXICO
Angio SS OCT in DME

13.55
V. Chong UK
The role of laser in DME

14.00
D. E. Pelayes argentina
New trends of pharmacotherapy in DME

14.05
F. Fayyad JORDAN
Mastering surgical management

14.10
F. March de Ribot SPAIN
Combining lines in DME and proliferative retinopathy

14.15
Discussion

14.30
End of session

Fri 02 13:45 - 14:30 CEST

Symposium Session 3: International Ocular Inflammation Society – Local Treatment of Noninfectious Posterior, Intermediate & Panuveitis: Pitfalls & Tips in 2020

Chairperson(s):
B. Bodaghi FRANCE, C. Pavesio UK

Channel 2

13.45
B. Bodaghi FRANCE
Overall role of local therapy and indications in NIU-PS

13.50
C. Pavesio UK
Local and/or systemic strategies: what is the best option for each patient?

13.55
Z. Habot-Wilner ISRAEL
Local therapeutic armamentarium: from A to Z

14.00
U. Pleyer GERMANY
Common complications of local therapies and their management

14.05
Q.D. Nguyen USA
Local Treatment in Development for Uveitis

14.10
M. de Smet SWITZERLAND
Best examples of therapeutic management in current practice

14.15
Discussion

14.30
End of session

Fri 02 14:00 - 14:45 CEST

EURETINA Session 3: Diabetic Retina

Chairperson(s):
R. Schlingemann THE NETHERLANDS, E. Midena ITALY

Channel 1

14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children

14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy

14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?

14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy

14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in

14.30
Discussion

14.45
End of session

Fri 02 14:45 - 15:30 CEST

Instructional Course 4: A New Era in the Treatment & Management of AMD: Understanding & Utilizing New Diagnostic & Treatment Options

Chairperson(s):
J. Monés SPAIN

Channel 3

14.45
J. Monés SPAIN
Introduction

14.50
G. Staurenghi ITALY
The new nomenclature for AMD

14.58
K. Csaky USA
The role of functional testing in AMD

15.06
J. Monés SPAIN
New and future treatments for AMD

15.14
Discussion

15.30
End of session

Fri 02 14:45 - 15:30 CEST

Symposium Session 4: RetinaTECH: Where technology meets surgery – a bio-engineering session

Chairperson(s):
S. Charles USA, T. Rossi ITALY

Channel 2

14.45
T. Rossi ITALY
Welcome and Introduction

14.48
T. Hassan USA
More options for wide-field viewing — back to the future

14.51
P. Stalmans BELGIUM
First reported clinical results from end-stage RP patients implanted with an innovative 3D- neural interface retinal prosthesis

14.54
S. Charles USA
Medium term PFO for inferior RDs, giant breaks (except superior) and macular patch grafts.

14.57
T. Rossi ITALY
Novel instrument for ILM, amniotic and retinal flap manipulation

14.59
D. Steel UK
Sphere of influence and fluctuations in flow during vitrectomy – effect of cutter design

15.02
M. De Smet SWITZERLAND
Optimizing subretinal delivery via robotics

15.05
S. Rizzo ITALY
A novel multi-function instrument

15.08
Discussion

15.30
End of session

Fri 02 15:00 - 15:45 CEST

EURETINA Session 4: Retinal Imaging, Artificial Intelligence, Big Data

Chairperson(s):
S. Wolf SWITZERLAND, N. Eter GERMANY

Channel 1

15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview

15.07
T. Peto UK
Artificial Intelligence for DR screening

15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI

15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans

15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers

15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications

15.27
Discussion

15.45
End of session

Fri 02 15:45 - 16:30 CEST

Instructional Course 5: Evidence-Based Treatment of Retinal Disease: How Practicing Clinicians Should Read Clinical Trials

Chairperson(s):
O. Zeitz GERMANY, A. Joussen GERMANY

Channel 3

15.45
T. Jackson UK
Designing, executing and interpreting randomized clinical trials

15.53
L. Kodjikian FRANCE
From randomized clinical trial to real-world: efficacy of VEGF inhibitors

16.01
O. Zeitz GERMANY
Understanding safety data: From adverse events to undesirable effects

16.08
A. Joussen GERMANY
Future developments in retina: scientific, clinical and other challenges for the pipeline

16.15
Discussion

16.30
End of session

Fri 02 15:45 - 16:30 CEST

Symposium Session 5: International academic and industry expert panel – Artificial-Intelligence (AI) Applications for Age-Related Macular Degeneration

Chairperson(s):
J. A. Hallak USA, F. G. Holz GERMANY, Maximilian Pfau GERMANY

Channel 2

15.45
N. Hammel USA
ML for predicting conversion to neovascular AMD

15.50
P. Keane UK
Predicting AMD progression using AI

15.55
L. de Sisternes USA
AMD-related biomarker extraction from optical coherence tomography (OCT) and OCT angiography data

16.00
J.A. Hallak USA
AI in neovascular AMD: prediction of injection requirements

16.05
Joint Discussion – State-of-the-art AI-applications for exudative AMD

16.15
M. Pfau GERMANY
Beyond RPE-atrophy: novel biomarkers to characterize retinal atrophy progression

16.20
S. Gao USA
Prediction of disease progression in AMD to improve clinical trial design

16.25
Joint Discussion – Unmet needs and future directions in Geographic Atrophy

16.30
End of session

Fri 02 16:00 - 16:45 CEST

EURETINA Session 5: RETINAWS

Chairperson(s):
K. Rezaei USA, R. Tadayoni FRANCE

Channel 1

16.00
M. Berrocal PUERTO RICO
Rescue the View

16.01
Discussion

16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome

16.05
Discussion

16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies

16.09
Discussion

16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa

16.13
Discussion

16.16
X. Li CHINA
Air-Fluid Exchange…

16.17
Discussion

16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage

16.21
Discussion

16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual

16.25
Discussion

16.28
S. Priglinger GERMANY
Submacular Perfluoron

16.29
Discussion

16.32
S. Rizzo ITALY
Disposable Cryo

16.33
Discussion

16.36
D. Steel UK
Perfluoron Guided Subretinal TPA

16.37
Discussion

16.40
R. Tadayoni FRANCE
TBD

16.41
Discussion

16.45
End of session

Sat 03 08:30 - 09:15 CEST

EURETINA Session 6: AMD

Chairperson(s):
F. G. Holz GERMANY, G. Staurenghi ITALY, A. Tufail UK

Channel 1

08.30
C.C.W. Klaver THE NETHERLANDS
New insights from epidemiological studies

08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans

08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD

08.45
Discussion

08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?

08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results

09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring

09.07
Discussion

09.15
End of session

Sat 03 08:45 - 09:30 CEST

Instructional Course 6: How to Improve Our Practice from Data Collected from Registry?

Chairperson(s):
C. Creuzot-garcher FRANCE, M. Gillies AUSTRALIA

Channel 3

08.45
C. Creuzot-Garcher FRANCE
From Clinical trial to registry: pros and cons

08.53
M. Gillies AUSTRALIA
Long term observational study, the FRB example in AMD

09.01
D. Barthelmes SWITZERLAND
Key learnings from FRB for clinical practice

09.09
V. Daien FRANCE
From registry data to nationwide study

09.17
Discussion

09.30
End of session

Sat 03 08:45 - 09:30 CEST

Symposium Session 6: The EuroVeRsion Case Contest

Chairperson(s):
A. Laidlaw UK, S. Saidkasimova UK

Channel 2

Panel: Y. Le Mer FRANCE, K. Krepler AUSTRIA, I. Relimpio SPAIN, M. Romano ITALY

08.45
C. Franco Ruedas SPAIN
Presentation 1: Retinal autograph in large refractory macular hole

08.48
Discussion

08.53
C. Iovino ITALY
Presentation 2: Human amniotic membrane plug in a patient with recurrent macular hole and atrophic AMD: what’s the best surgical approach?

08.56
Discussion

09.01
J.B. Ducloyer FRANCE
Presentation 3: Gene therapy: a new complication

09.04
Discussion

09.09
M. Sommer AUSTRIA
Presentation 4: ”Fiat Lux”- A sleeve for vitrectomy light probe modification

09.12
Discussion

09.17
F. Sabatino UK
Presentation 5: ILM flap for the optic disc pit maculopathy

09.20
Discussion

09.25
Announcement of the winner

09.30
End of session

Sat 03 09:30 - 10:15 CEST

EURETINA Session 7: Retinal Vascular Diseases

Chairperson(s):
A. Loewenstein ISRAEL, N. Eter GERMANY

Channel 1

09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion

09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion

09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion

09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?

09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease

10.00
Discussion

10.15
End of session

Sat 03 09:45 - 10:30 CEST

Symposium Session 7: Management of the Macula in Rhegmatogenous Retinal Detachment Repair

Chairperson(s):
A. Grabowska UK, T. Williamson UK

Channel 2

Show details

09.45
T. Williamson UK
Introduction and Natural history of RRD

09.49
J. van Meurs THE NETHERLANDS
Pre-operative assessment and management of the macula in RRD

09.53
A. Grabowska UK
Pre-operative management of the macula in PPV for RRD

09.57
D. Yorston UK
Immediate postoperative posturing

10.01
R.J. Hillier UK
Pneumatic retinopexy vs PPV

10.05
T. Williamson UK
Management of the macular displacement and macular folds

10.09
A. Grabowska UK
PVR, retinectomy and the macula

10.13
Discussion

10.30
End of course

Sat 03 09:45 - 10:30 CEST

Instructional Course 7: Vitreomacular Interface Abnormalities: From Bench to Bedside

Chairperson(s):
E. Pilotto ITALY, R. Schumann THE GERMANY

Channel 3

09.45
R. Schumann GERMANY
Premacular membranes in humans: histologic evidence for different cell populations in fibrotic process

09.51
E. Pilotto ITALY
Morphofunctional evaluation in vitreomacular interface abnormalities

09.57
N. Lois UK
Vitreomacular interface abnormalities in diabetic macular oedema

10.03
R. Frisina ITALY
Surgery in idiopathic cases

10.09
M. de Smet NETHERLANDS
Can robotics contribute to the performance of vitreomacular surgery?

10.15
Discussion

10.30
End of session

Sat 03 10:30 - 11:15 CEST

EURETINA Session 8: Uveitis/Endophthalmitis

Chairperson(s):
J. Garcia-Arumi SPAIN, J. van Meurs THE NETHERLANDS

Channel 1

10.30
B. Bodaghi FRANCE
Viral retinitis

10.36
A. Adan SPAIN
New strategies with biologics in uveitis

10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis

10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis

10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis

11.00
Discussion

11.15
End of session

Sat 03 10:45 - 11:30 CEST

Instructional Course 8: OCT Angiography: How to Understand What We See

Chairperson(s):
J. F. Korobelnik FRANCE

Channel 3

10.45
G. Staurenghi ITALY
Overview on OCTA

10.51
J. Figueira PORTUGAL
OCTA in Diabetic Retinopathy

10.57
N. Eter GERMANY
OCTA in AMD

11.03
M. B. Rougier FRANCE
OCT A and optic disc

11.09
J. F. Korobelnik FRANCE
Quantification in OCT-A: what for?

11.15
Discussion

11.30
End of session

Sat 03 10:45 - 11:30 CEST

Symposium Session 8: SLAM! Organized by young retinal specialists (YOURS)

Channel 2

10.45
Introduction – YOURS committee
C. Dysli SWITZERLAND,
E. de Carvalho UK ,
L. Kuehlewein GERMANY,
R. Mastropasqua ITALY,
Y. Subhi DENMARK,
E. van Dijk THE NETHERLANDS

10.47
C. Iovino ITALY
Photodynamic therapy induced choroidal changes in central serous chorioretinopathy – experience from different countries

10.52
G. Ledesma Gil MEXICO/UK
Don’t throw your fluorescein angiography machine away yet

10.57
M. Bagger DENMARK
The hangman game of uveal melanoma

11.02
R. D’Aloisio ITALY
From smallfield to widefield OCTA in retinal vascular diseases

11.07
T. Nguyen THE NETHERLANDS
Two-year prospective follow-up in patients with CRB1-associated retinal dystrophies: paving the way towards gene therapy

11.12
T. Heeren UK
The end stage of Macular Telangiectasia type 2

11.17
Discussion and announcement of the winner of the Science Slam

11.28
Announcement winner Ophthalmologica lecture

11.30
End of session

Sat 03 12:30 - 13:00 CEST

Keynote Lecture – EURETINA Lecture

Channel 1

Show details KEY

12.30
R. Spaide USA
Reconsidering Pachychoroid and What it Means

Sat 03 13:00 - 13:30 CEST

Keynote Lecture – Kreissig Lecture

Channel 1

Show details KEY

13.00
M. S. Figueroa SPAIN
Plasma Rich in Growth Factors for Macular Holes in High Myopia

Sat 03 13:30 - 14:15 CEST

Instructional Course 9: Pneumatic Retinopexy: Practical Tips, Evidence Base & Role in Contemporary Retinal Detachment Repair

Chairperson(s):
R. Hillier UK, R. Muni CANADA

Channel 3

13.30
R. Hillier UK
Welcome (including audience poll – ‘How many audience members currently incorporate pneumatic retinopexy into their routine clinical practice?’)

13.32
P. Kertes CANADA
Review of the Pneumatic Retinopexy Trial findings

13.34
R. Hillier UK
Top line findings of the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT) and post hoc analyses

13.36
R. Muni CANADA
Top line findings of the Retinal Displacement Detected with Fundus Autofluorescence Imaging following Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Studies (INTEGRITY and ALIGN)

13.38
R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Principles of intraocular gas

13.42
P. Kertes CANADA
The fundamentals of pneumatic retinopexy technique: Case selection

13.46
R. Muni CANADA, R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Step-by-step surgical technique (‘the PIVOT method’)

13.54
E. Mavrikakis GREECE
The fundamentals of pneumatic retinopexy technique: Management of complications

13.58
R. Hillier UK, R. Muni CANADA, P. Kertes CANADA, E. Mavrikakis GREECE
Practical pearls and pitfalls when starting out: panel ‘round robin’ discussion

14.06
Discussion

14.15
End of session

Sat 03 13:30 - 13:15 CEST

Amsterdam Retina Debate

Chairperson(s):
S. Lesnik-Oberstein THE NETHERLANDS

Channel 2